/ATHJF
ATHJF Stock - Antisense Therapeutics Limited
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$0.01-76.00%
$0.04 (-76.00%) • Sep 13
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATHJF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.87
52W High$0.07
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.97M | $1.58M | $1.78M | $577,764 | $668,433 |
| Gross Profit | $2.91M | $1.48M | $1.69M | $474,445 | $560,832 |
| Gross Margin | 97.9% | 94.0% | 95.0% | 82.1% | 83.9% |
| Operating Income | $-11,832,514 | $-13,344,975 | $-7,611,229 | $-8,683,281 | $-6,666,293 |
| Net Income | $-11,919,223 | $-11,379,828 | $-5,811,810 | $-8,060,639 | $-5,908,202 |
| Net Margin | -401.6% | -720.3% | -326.9% | -1395.1% | -883.9% |
| EPS | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 |
Company Overview
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATHJFBeat Rate
88%
Last 8 quarters
Avg Surprise
+34.7%
EPS vs Estimate
Beats / Misses
7/1
Last 12 quarters
Latest EPS
$-0.00
Q3 2024
EPS Surprise History
Q2 21
+19.3%
$-0.01vs$-0.01
Q4 21
+64.3%
$-0.00vs$-0.01
Q2 22
No data
Q3 22
+60.0%
$-0.00vs$-0.01
Q4 22
+28.1%
$-0.01vs$-0.01
Q2 23
+39.3%
$-0.01vs$-0.01
Q1 24
+18.2%
$-0.00vs$-0.01
Q3 24
-15.3%
$-0.00vs$-0.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 27, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Nov 14, 2024 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | $-0.00 | $-0.00 | -15.3% | ✗ MISS |
Q2 2024 | Apr 29, 2024 | — | — | — | — |
Q1 2024 | Feb 28, 2024 | $-0.01 | $-0.00 | +18.2% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.01 | $-0.01 | +39.3% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-0.01 | $-0.01 | +28.1% | ✓ BEAT |
Q3 2022 | Aug 31, 2022 | $-0.01 | $-0.00 | +60.0% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | $-0.01 | $-0.00 | +64.3% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $-0.01 | $-0.01 | +19.3% | ✓ BEAT |
Q4 2020 | Dec 30, 2020 | $-0.01 | $-0.00 | +63.7% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 30, 2018 | — | $-0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q4 2017 | Dec 30, 2017 | — | $-0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ATHJF
What is ATHJF's current stock price?
Antisense Therapeutics Limited (ATHJF) is currently trading at $0.01 per share. The stock has moved -76.00% today.
What is the analyst price target for ATHJF?
No analyst price targets are currently available for this stock.
What sector is Antisense Therapeutics Limited in?
Antisense Therapeutics Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is ATHJF's market cap?
Antisense Therapeutics Limited has a market capitalization of $0.02 billion, making it a small-cap company.
Does ATHJF pay dividends?
No, Antisense Therapeutics Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBFFTF
Biofrontera AG
$0.33
Mkt Cap: $0.0B
GRAMF
TPCO Holding Corp.
$0.16
Mkt Cap: $0.0B
KMSTF
Kadimastem Ltd
$3.21
Mkt Cap: $0.0B
NXTTF
Lifeist Wellness Inc.
$0.04
Mkt Cap: $0.0B
OCEL
Organicell Regenerative Medicine, Inc.
$2.74
Mkt Cap: $0.0B
PKANF
Simply Better Brands Corp.
$0.21
Mkt Cap: $0.0B
RAMMF
RAMM Pharma Corp.
$0.06
Mkt Cap: $0.0B
TGPHF
Together Pharma Ltd
$0.09
Mkt Cap: $0.0B
VILGF
Yourgene Health Plc
$0.00
Mkt Cap: $0.0B
VNNYF
Vinergy Capital Inc.
$0.15
Mkt Cap: $0.0B
Explore stocks similar to ATHJF for comparison